D630037F22Rik Activators
Tbc1d32, a member of the TBC1 domain family, plays a crucial role in diverse processes such as animal organ development, non-motile cilium assembly, and smoothened signaling pathways involved in dorsal/ventral neural tube patterning. Activation of Tbc1d32 can be influenced by various chemicals targeting different cellular pathways. Lithium chloride indirectly activates Tbc1d32 by inhibiting GSK-3β, enhancing non-motile cilium assembly. Tofacitinib, a JAK inhibitor, indirectly activates Tbc1d32 by modulating the JAK/STAT pathway, influencing animal organ development. Forskolin stimulates the cAMP/PKA pathway, indirectly enhancing Tbc1d32-associated processes like animal organ development. Trichostatin A, an HDAC inhibitor, indirectly activates Tbc1d32 by influencing gene expression and signaling pathways, potentially improving animal organ development.
Chloroquine, an autophagy inhibitor, influences non-motile cilium assembly, enhancing Tbc1d32 function. SB203580, a p38 MAPK inhibitor, indirectly activates Tbc1d32 by modulating smoothened signaling pathways, improving dorsal/ventral neural tube patterning. Retinoic acid, a vitamin A derivative, indirectly activates Tbc1d32 by influencing animal organ development. Rapamycin, an mTOR inhibitor, enhances Tbc1d32-associated processes like non-motile cilium assembly. SP600125, a JNK inhibitor, indirectly activates Tbc1d32 by influencing smoothened signaling pathways, improving dorsal/ventral neural tube patterning. Ionomycin, a calcium ionophore, indirectly activates Tbc1d32 by influencing calcium signaling, enhancing non-motile cilium assembly. SB431542, a TGF-β receptor inhibitor, indirectly activates Tbc1d32, influencing animal organ development. Niclosamide, a Wnt/β-catenin pathway inhibitor, indirectly enhances Tbc1d32 by modulating smoothened signaling pathways, improving dorsal/ventral neural tube patterning. Understanding Tbc1d32's activation mechanisms sheds light on its versatile functions in developmental processes, offering potential insights into conditions such as Bardet-Biedl syndrome, Meckel syndrome, VACTERL association, and visceral heterotaxy. These findings contribute to unraveling the intricate regulatory networks orchestrating Tbc1d32's roles in cellular and developmental contexts.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride, a GSK-3β inhibitor, indirectly activates Tbc1d32. Inhibition of GSK-3β enhances non-motile cilium assembly, a process associated with Tbc1d32. Lithium chloride's action on the Wnt pathway, involving GSK-3β, may influence Tbc1d32, contributing to up-regulation of non-motile cilium assembly. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase (HDAC) inhibitor, indirectly activates Tbc1d32. HDAC inhibition can influence gene expression and signaling pathways. Trichostatin A's impact on epigenetic regulation may modulate Tbc1d32-associated processes, such as animal organ development, leading to increased Tbc1d32 expression and contributing to enhanced developmental processes. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, an autophagy inhibitor, indirectly activates Tbc1d32. Autophagy plays a role in non-motile cilium assembly, a process associated with Tbc1d32. Inhibiting autophagy with chloroquine may influence Tbc1d32 function, potentially up-regulating non-motile cilium assembly. Chloroquine's impact on autophagy could contribute to the enhanced activation of Tbc1d32 and promote non-motile cilium assembly. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, indirectly activates Tbc1d32. The p38 MAPK pathway is involved in smoothened signaling, which affects dorsal/ventral neural tube patterning associated with Tbc1d32. Inhibiting p38 MAPK may influence this pathway, potentially up-regulating Tbc1d32 and contributing to enhanced dorsal/ventral neural tube patterning. SB203580's action on the p38 MAPK pathway could lead to the up-regulation of Tbc1d32 and promote improved patterning. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a vitamin A derivative, indirectly activates Tbc1d32. Retinoic acid is involved in animal organ development, a process associated with Tbc1d32. Modulating retinoic acid signaling may influence Tbc1d32, contributing to the up-regulation of animal organ development. Retinoic acid's impact on developmental signaling could enhance Tbc1d32 expression, promoting improved animal organ development. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly activates Tbc1d32. The mTOR pathway is implicated in non-motile cilium assembly, a process associated with Tbc1d32. Inhibiting mTOR with rapamycin may influence Tbc1d32, potentially up-regulating non-motile cilium assembly. Rapamycin's action on the mTOR pathway could contribute to the enhanced activation of Tbc1d32 and promote non-motile cilium assembly. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly activates Tbc1d32. The JNK pathway is involved in smoothened signaling, affecting dorsal/ventral neural tube patterning associated with Tbc1d32. Inhibiting JNK may influence this pathway, potentially up-regulating Tbc1d32 and contributing to enhanced dorsal/ventral neural tube patterning. SP600125's action on the JNK pathway could lead to the up-regulation of Tbc1d32 and promote improved patterning. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin, a calcium ionophore, indirectly activates Tbc1d32. Calcium signaling is associated with non-motile cilium assembly, a process involving Tbc1d32. Elevating intracellular calcium levels with ionomycin may influence Tbc1d32, potentially up-regulating non-motile cilium assembly. Ionomycin's impact on calcium signaling could contribute to the enhanced activation of Tbc1d32 and promote non-motile cilium assembly. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly activates Tbc1d32. TGF-β signaling is implicated in animal organ development, a process associated with Tbc1d32. Inhibiting TGF-β receptors may influence Tbc1d32, contributing to the up-regulation of animal organ development. SB431542's action on the TGF-β pathway could enhance Tbc1d32 expression, promoting improved animal organ development. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide, a Wnt/β-catenin pathway inhibitor, indirectly activates Tbc1d32. Wnt signaling is involved in smoothened signaling, affecting dorsal/ventral neural tube patterning associated with Tbc1d32. Inhibiting Wnt/β-catenin signaling with niclosamide may influence Tbc1d32, potentially up-regulating Tbc1d32 and contributing to enhanced dorsal/ventral neural tube patterning. Niclosamide's action on Wnt/β-catenin signaling could lead to the up-regulation of Tbc1d32 and promote improved patterning. | ||||||